Safety of linezolid in patients with decreased renal function and trough monitoring: a systematic review and meta-analysis

Xiaoxi Liu, Mari Aoki, Sumika Osa, Chihiro Ito, Reika Saiki, Tomoya Nagai, Yuki Enoki, Kazuaki Taguchi, Kazuaki Matsumoto

Research output: Contribution to journalArticlepeer-review

Abstract

Background: Linezolid causes hematological toxicity, mostly thrombocytopenia, which leads to treatment discontinuation and failure. Recent studies revealed that during linezolid therapy, the incidence of treatment-related hematological toxicity is significantly higher in patients with decreased renal function (DRF) than in those with normal renal function. Linezolid monitoring is necessary due to the high frequency of hematological toxicity in patients with DRF and the relationship between blood concentration and safety. We performed a systematic review and meta-analysis to evaluate the safety correlation between DRF and trough monitoring. Methods: Articles published before June 24, 2022, on MEDLINE, Web of Sciences, Cochrane Register of Controlled Trials, and ClinicalTrials.gov were systematically analyzed. Odds ratios (ORs) and 95% confidence intervals (CIs) were calculated using the Mantel–Haenszel method and the variable effects model. Results: The incidence of hematological toxicity was significantly higher in patients with DRF than in those without DRF (OR = 2.37; p < 0.001). Subgroup analysis, performed according to hematotoxicity classification, including thrombocytopenia, anemia, and pancytopenia, revealed a significantly higher incidence of thrombocytopenia (OR = 2.45; p < 0.001) and anemia (OR = 2.31; p = 0.006) in patients with DRF than in those without; pancytopenia (OR = 1.41; p = 0.80) incidences were not significantly higher. Based on a systematic review, linezolid trough concentrations > 6–7 μg/mL may be associated with an increased incidence of thrombocytopenia. However, no confidential threshold values for the development of thrombocytopenia were found in the area under the concentration curve values for children or adults. Conclusion: We observed a high frequency of hematological toxicity during linezolid therapy in patients with DRF. To ensure safety, linezolid trough concentrations should be ≤6–7 μg/mL.

Original languageEnglish
Article number89
JournalBMC Pharmacology and Toxicology
Volume23
Issue number1
DOIs
Publication statusPublished - 2022 Dec

Keywords

  • Hematological toxicity
  • Linezolid
  • Renal
  • Thrombocytopenia
  • Trough concentrations

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Fingerprint

Dive into the research topics of 'Safety of linezolid in patients with decreased renal function and trough monitoring: a systematic review and meta-analysis'. Together they form a unique fingerprint.

Cite this